#HRD testing

[gallifreyinstituteforlearning]

🩺 Sepsis Emergency Response (SER)

Is your sick Gallifreyan displaying signs of Sepsis? Here's a handy guide on how to respond to this medical emergency, because 'Sepsis is SER-ious'.

BIGGER - Google Drive: PDF / Image JPG / Image PNG

This guide is for use on Gallifreyans and Time Lords only. Always seek your human advice from human health providers.

✨ What is Sepsis?

Sepsis is a very rare but very serious condition in Gallifreyans that requires immediate action. It occurs when the immune system overreacts to an infection, leading to widespread inflammation and potentially life-threatening complications like hearts failure or regeneration.

While Gallifreyan immune systems are extremely resilient, sepsis can develop unexpectedly, especially after trauma or severe infections, requiring immediate attention.

Just remember, sepsis is SER-ious.

📈 What's New in SER?

This updated version of SER adds a few key details previously not addressed, including the use of vasopressors and fluid bolus administration. It also introduces a few new visuals to highlight the importance of GASS, and better notes on oxygen administration.

📝 How to Use SER

📈 Step 1: Recognising Sepsis

Use the GASS system to assess vital signs and determine if sepsis is indicated:

Scores ≥9 or 3 in any category require immediate activation of the sepsis protocol.

Symptoms such as persistent abnormal breathing, synchronous hearts rhythm, or a significant Heart Rate Differential (HRD ≥50 bpm) are present.

If sepsis is identified, start regular routine monitoring using GASS, either continuously or every 15 minutes.

If the patient's vitals indicate a healing coma, cease active intervention and monitor in a secure environment.

🫁 Step 2: Secure the Airway

Check and clear any obstructions using ABCDE protocols before introducing supplemental oxygen.

Ensure the patient is not using their respiratory bypass system, as introducing oxygen during respiratory bypass activation may cause oxygen toxicity.

Administer oxygen cautiously. Start at 10L/min and titrate to the lowest effective flow rate to maintain respiratory function.

If oxygen equipment is unavailable, focus on positioning the patient to optimise natural airflow, ensuring the head and neck remain elevated.

If using human equipment, use oxygen cautiously and rely on clinical observation rather than human oximeters, as these are ineffective on Gallifreyans.

🧪 Step 3: Take Bloods

Establish an IV line and collect blood samples for analysis.

Test for lactate levels (≥1 mmol/L indicates significant infection).

If possible, test for artron (≥5000 mcL) and lindos (≥250 mcL) levels. Elevated markers confirm severe immune response or systemic distress.

Gallifreyan blood samples can be challenging to analyse with human equipment—if Gallifreyan equipment is not available, rely on lactate levels and visible symptoms like pallor, sweating, or poor capillary refill time.

💉 Step 4: Introduce Intravenous Antibiotics

Administer antibiotics immediately via IV.

Gallifreyan dosages are double human normals.

If the infection is unknown, administer broad-spectrum antibiotics according to your local policy (eg. Amoxicillin/Doxycycline)

Adjust to targeted antibiotics if the infection source is identified.

Timing matters: Administer antibiotics within the first hour of sepsis identification to maximise effectiveness and reduce complications.

💧 Step 5: Administer Fluids

Administer fluid bolus through an IV line. Glalifreyans preferelectrolyte-rich solutions (e.g., Hartmann’s or 0.9% Sodium Chloride).

Administer a 500ml bolus over 15–30 minutes if systolic BP ≤90 mmHg or lactate ≥1 mmol/L.

Reassess after each bolus and repeat up to four times as needed.

Monitor for signs of fluid overload, such as jugular vein distension or rising respiratory distress.

Reduce bolus volume to 250ml if heart/s failure is suspected to prevent fluid overload.

🩸 Step 6: Consider a Blood Transfusion

If the patient fails to stabilise after antibiotics and fluids or has had significant blood loss, consider a transfusion:

Efficacy:

Human blood: 50%.

Gallifreyan (same House): 70%.

Own blood: 90%.

⚠️USE ONLY COMPATIBLE BLOOD. Gallifreyans are unable to receive blood transfusions from other Gallifreyans who are not in their House, which will cause severe complications.

⚠️DO NOT USE VASOPRESSORS. Gallifreyan physiology is sometimes susceptible to blood clots from human drugs that affect vascular tone, leading to severe complications.

🔁 Step 7: Reassess and Monitor

Use the ABCDE approach alongside GASS to monitor the patient’s condition every 15 minutes.

Escalate care if:

GASS score remains ≥9.

Severe symptoms like synchronised hearts rhythm persist.

The GASS score worsens by more than 3 points across consecutive assessments.

Always consult a Gallifreyan hospitaller for advanced treatment.

📌 Key Points to Remember

Early Action Saves Lives: Use GASS to identify sepsis early and act fast.

Monitor and Reassess: Frequent reassessment is critical to adapt care as needed.

Tailored Interventions: Adjust fluids, antibiotics, and oxygen based on the patient's unique physiology.

Escalate When Needed: Always involve a Gallifreyan medic or hospitaller if symptoms persist or worsen.

Caregiver Vigilance: Gallifreyan physiology can mask symptoms until sepsis is advanced, so remain alert.

Medical Guides These are all practical guides to assessing and treating a Gallifreyan in an emergency or medical setting.

⚕️💕Gallifreyan CPR

⚕️👽Gallifreyan Assessment Scoring System (GASS)

⚕️👽ABCDE Assessment

⚕️⚠️Sepsis Emergency Response (SER)

⚕️⚠️Severe Trauma Protocol

⚕️🌡️Gallifreyan Thermoregulation and Emergency Response

⚕️🔮Psionic Emergency Pathways

⚕️✨Post-Regeneration Management

⚕️💤Gallifreyan Healing Coma Management

⚕️🩸Interpreting Gallifreyan Bloodwork

⚕️👶Gallifreyan Paediatric Emergencies

Any orange text is educated guesswork or theoretical. More content ... →📫Got a question? | 📚Complete list of Q+A and factoids →📢Announcements |🩻Biology |🗨️Language |🕰️Throwbacks |🤓Facts → Features:⭐Guest Posts | 🍜Chomp Chomp with Myishu →🫀Gallifreyan Anatomy and Physiology Guide (pending) →⚕️Gallifreyan Emergency Medicine Guides →📝Source list (WIP) →📜Masterpost If you're finding your happy place in this part of the internet, feel free to buy a coffee to help keep our exhausted human conscious. She works full-time in medicine and is so very tired 😴

[kumoriyami-xiuzhen]

Hakuoki Drama CD Hijikata Biyori Track 35 Eng

After track 36, I think there are 4 biyori specials I've got tl for that remain untranslated (though I'm not 100% sure of that...), and then I'm sorta debating about translating the Hakuoki x Sengoku Night Blood crossover main story (I can't do anything but the main story, which is in 5 parts 😅. also this is all your fault koto 😝).

Anyway, this month, I'm likely just going to stick to posting on Friday or Saturday. My workday ends at 2pm on Friday this month so it'll probably be easier to post then... that is assuming I can finish game testing beforehand (been speed-running but it takes time...).

Hakuoki Hijikta Biyori Track 35: Return

English translation by KumoriYami

Hijikata: I'm, back.

Kondou: Ooh, you've worked hrd, Toshi.

Hijikta: Oh?....What, it's just Kondou-san.

Kondou: What? That's a terrible thing to say.

Hijikta: Haha, Sorry. I thought one of the other members would be here.

Kondou: Ahahaha... I see, I see/really, really. Were they scared by me? It seems that I did something wrong to Toshi.

Hijikta: No, it's nothing like that…

Kondou: Come on, don't stand there forever, come inside and go get some rest.

Toudou: The Eighth Division has returned!

Kondou: Oh! It's Heisuke. Thank you for your hard work.

Hijikata: Good work.

Toudou: Hey what's going on? You two are actully greeting me? What happened?

Hijikta: What are you saying. I just got back too.

Toudou: Oh, I see. I was really surprised since I thought that something had hppened for Kondou-san and Hijikata-san to come greet me. Well, this makes me feel better.

Hijikata: Then you'll have to work hard to make up for it.

Kondou: Oh, that's right. Heisuke even looks like he wants to keep working.

Toudou: What!? Wait, even Kondou-san!

Kondou: Hahahaha! I ws just kidding, just kidding! You can head inside and go rest, Heisuke.

Hijikata: Sorry, Kondou-san.

Kondou: What's wrong, why raeyou suddenly saying that. s, all of a sudden.

Hijikata: Ah... You obviously have things to do, and I kept you here.

Kondou: What are you talking about?

Hijikata: You were going to go somewhere, weren't you? You were at standing right by the entrance… Toudou: Ah, what. If that's the case, just say that, Kondou-san. I'll open this now, so wait a moment.

Kondou: No, I wsan't going anywhere.

Hijikata: Huh?

Todou: Really?

Hijikata: If you weren't going anywhere, what were you doing here?

Kondou: I wsa only thinking that you'd be returning soon, so I came to greet you.

Hijikata: Is that all?

Kondou: That's right…

Hijikata:…What's wrong, Kondou-san?

Kondou: Should I not have?

Hijikata: No, it's not like that…

Todou: Thank you, Kondou-san! I, Todou Heisuke, have returned safely!

Kondo: Nn, I see. I'm glad that you're safe.

Toudou: Of course. Kondou-san really worries a lot. Right, Hijikta-san.

Hijikata: Yeah… that's right. Kondou-san, we're not that weak. We'll definitely return safely. So, don't waste your precious time on something trivial like this.

Toudou: Yes, that's right.

Kondou: I see. Haha, that's true. But… I've had a lot of things to worry about lately.

Hijikata: In that case, I'll at least get rid of one of them. Hijkta Toshizou has safely returned.

Kondou: Ah, welcome back, Toshi.

---end---

[itsjournalfi]

Bismillaahirrahmaanirrahiim ...

Saya ingin hikmah ini tersampaikan, tidak berhenti di kehidupan saya. Izin menulis dan terima kasih berkenan membaca.

Saya sudah merencanakan untuk menuliskan sedikit atau nanti mungkin menjadi terlalu panjang yang diceritakan, perjalanan di Rutaba MQA selama 2 tahun ini. Semoga bisa tersampaikan pesan yang menjadi ibrah selama berjalan di jalan ini atau mungkin ada hal yang tidak baik -seyogiyanya saya hanya manusia biasa yang masih jauh dari kata sempurna.

12 Juli 2022, saya masih ingat. Hari itu saya berangkat ke Rutaba MQA untuk ketiga kalinya untuk mulai mukim. Setelah pertama adalah saat test wawancara, kedua adalah test microteaching pada recruitment guru baru di Yayasan MQA.

Lantaran memiliki koneksi dengan Mas Angga Feri Setiawan, trainer Nasional sekaligus menjadi HRD Rutaba MQA pada saat itu. Saya juga hendak berterima kasih karena beliau informasi recruitment ini tersampaikan kepada saya.

Back to~

Pada saat itu sudah hafal lah jalan menuju sekolah setelah sebelumnya pada kali pertama mencari alamat Rutaba MQA, seperti dipermainkan oleh google maps hingga hampir mengurungkan diri menuju sekolah karena salah terus masuk gang. Dan ternyata ini adalah menjadi ujian pertama Allah Swt. untuk saya bisa menghadapi tantangan-tangangan selanjutnya di jalan dakwah ini.

Katanya, ada 60 an pendaftar yang masuk di link formulir. Tersaring melalui tahap administrasi, kemudian wawancara, terakhir microteaching. Tersaringlah hanya 3 yang akhirnya masuk menjadi bagian dari Rutaba Team MQA, yaitu Ust Sofi; yang pada saat kali pertama berkenalan saya kira masih singlelillah (hihii) ternyata sudah ada anak 1 dan ternyata lagi beliau asli alamat sedesa dengan saya, hanya saja sekarang pindah alamat di Sumbang. Kedua ada Ustazah Naila, kesan pertama beliau perempuan lemah lembut, sopan santun dan benar menjadi teman yang baik sampai saat ini. Dan ketiga adalah saya sendiri.

3 orang ini, saya yakin adalah pilihan Allah Swt. untuk diizinkan belajar di Rutaba MQA, ditempa melalui ujian-ujian yang Allah kasih di setiap inci perjalanan di sana, berjuang dengan kesibukan masing-masing -selain beraktivitas di lingkungan Rutaba MQA. Kami diizinkan menjadi bagian dari Yayasan MQA, bisa mengenal dan membersamai jalan dakwah Umi Waliko, bisa berteman dan saling bahu membahu dengan teman-teman yang sudah lebih lama mengabdi di Yayasan MQA.

Sampai sekarang saya pun masih berpikir. Memutar alur dengan 'jika.'

~ Jika saya pada saat itu tidak mendapat info recruitment guru dari Mas Angga.

~ Jika saya menyerah dari google maps yang mempermainkan (hehe:D)

~ Jika saya tidak diberikan kesempatan berproses di Rutaba MQA.

~ ---

--- Saya tidak akan pernah menjadi perantau di sudut Banteran yang agak jauh dari peradaban kota Purwokerto.

--- Saya yakin akan beproses di tempat dan jalan yang lain jika tidak di Rutaba. Namun saya yakin tidak akan sebaik jika tidak ditempatkan pada perjalanan yang sudah Allah tetapkan di Rutaba MQA ini.

--- Saya tidak akan tahu rasanya memanage waktu untuk kuliah, berorganisasi, dan mengajar, serta untuk keluarga di rumah yang tetap harus saya prioritaskan.

--- Saya belajar bertanggung jawab untuk setiap amanah yang dilimpahkan.

--- Saya menjadi lebih bisa mengenali diri sendiri. Karena katanya karakter seseorang akan terlihat ketika ada di masa genting/dihadapkan masalah/tantangan baru. Dengan adanya beberapa to do list yang merayap setiap hari dan harus dihadapi, saya menjadi lebih mengenali diri. Bahwa ternyata saya bisa menghendle suatu agenda yang sekolah tugaskan untuk saya, bahwa ternyata saya bisa melakukan ini, melakukan itu.

--- Jika saya tidak berproses di Rutaba, saya tidak akan belajar di waktu yang lebih cepat dari ini untuk memahami dunia balita dan seusia TK, bagaimana cara berkomunikasi dengan mereka, bagaimana cara belajar dan bermain bersama mereka, bagaimana cara mengurus anak dari beberapa bagian yang saya bisa lakukan maupun mengetahui melalui pengamatan terhadap teman yang mengurus anak daycare.

--- Satu hal tak kalah penting, jika saya tidak di Rutaba MQA, saya tidak akan memiliki circle sebaik teman2 asatidz. Saya belajar dari mereka, terutama Umi Waliko yang menjadi role model perempuan penggerak desa. Saya belajar optimis dari Umi. Saya belajar 'yakin', usaha, doa, dan pasrah pada YME dari beliau. Jika mungkin saya sudah memiliki konsep ini jauh dari sebelum saya mengenal Umi, namun praktik real life nya saya menemukan di sosok Umi.

--- Seiring berjalannya waktu, semakin melekat pemahaman tentang memantaskan diri di hadapan Allah. Bahwa sebagai seorang guru kita harus terus mengupgrade diri. Jika pada saat itu metode pengajaran yang digunakan di Rutaba MQA adalah metode WAFA, saya berusaha untuk mempelajari metode itu. Maka mendekatkan pada ahlinya adalah jalan yang saya tempuh, belajar dengan Ustazah Seli.

✯ Seorang guru senantiasa berusaha memantaskan diri di hadapan Allah, karena Allah tidak akan tidak memberikan kenikmatan lebih pada seorang hamba kecuali ia telah berusaha menjadi lebih baik dari sebelumnya.

--- Di Rutaba MQA, saya menjadi lebih memahami bahwa komunikasi adalah hal yang penting. Jadwal kuliah jika bentrok dengan jam mengajar, suatu agenda sekolah jangan sampai terjadi miss, cara berinteraksi dengan wali santri, cara bergaul dengan anak didik. Semua itu butuh komunikasi yang baik. Dan itu bisa dipelajari selama mengahadapinya.

--- Saya bisa belajar lebih banyak kesempatan untuk berbicara di hadapan orang banyak.

--- ✯ Berapapun ilmu yang sudah kita dapat, membagikan dengan orang lain tentu akan membuat ilmu itu semakin melekat di otak atau hati kita.

--- Jika saya tidak di Rutaba MQA, mungkin saya tidak lebih baik memahami tentang konsep rezeki. Bahwa rezeki bukan hanya berbentuk uang. Namun juga kehidupan yang baik itu sendiri, teman yang baik dan mau mengingatkan, anak soleh yang mendoakan, kelapangan hati, pemahaman tentang kehidupan, dan rasa rida pada setiap ketetapanNya; -semua itu rezeki.

Semoga ini menjadi aset pertama, memiliki anak didik di sudut Sumbang sana. Yang kelak mereka akan selalu hidup bersama Al-Quran. Semoga setiap huruf yang mereka baca dan amalkan di sepanjang hidupnya nanti, menjadi jariyah tak terputus bagi saya, --bagi asatidz MQA.

◈ Banyak POV dan ilmu baru yang saya dapat dari obrolan, nasihat, kala acara Parenting Balita maupun Madin pada materi yang disampaikan Umi. Entah jika saya tidak berada di jalan ini, bisakah lebih cepat dari ini untuk mendapat pelajaran itu semua. Alhamdulillahirabbil 'aaalamiin.

--- Jika saya tidak di Rutaba MQA, saya tidak akan memahami betapa mulia menjadi guru ngaji. Yang mungkin hanya dipandang sebelah mata oleh beberapa lapis masyarakat. Namun di sini saya merasakan faedah yang besar, bahu membahu bersama teman asatidz, _ngopeni_ anak menuntut ilmu, belajar Al-Quran; -dari semua elemen bekerja sama (orang tua, guru, anak2). Seyogiyanya semua ranah mulia dan diridai selama di jalanNya.

◈ Saya merasakan hikmah bagi diri sendiri selama ini. Banyak hal yang memotivasi dan kadang ada yang melunturkan semangat karena fitrah emosi atau hormon perempuan yang dilimpahi oleh Allah Swt. Namun, apalah jadinya jika saya tidak mau melawan penghalang itu.

✯ Sudut pandang bagi kehidupan, bahwa bagi siapa yang mau mengurus agama Allah, maka Allah lah yang langsung mengurus dan menyelesaikan urusan kita.

~ Kebanyakan dan saya sendiri pun pasti memiliki rasa khawatir jikalau saya kuliah sambil mengajar akan terganggu waktu kuliah, waktu belajar, waktu mengerjakan tugas, ataupun akan menjadi punya sedikit kesempatan hangout bersama teman2 kampus karena kesibukan mengajar di Rutaba MQA.

Namun, karena saya langsung dihadapkan oleh keadaan;

mengharuskan saya bisa membagi waktu. Maka hal itu bisa terhendel selama bisa menerapkan managing waktu yang baik.

✯ Untuk sesuatu yang dibayangkan dan akan sulit dihadapi, namun kenyataannya bisa terlewati.

Sempat saya merasa khawatir untuk beban bersamaan: kuliah, organisasi, mengajar di Rutaba, les privat, mengerjakan tugas akhir (skripsi), pada saat itu juga ada list target mempersiapkan ujian WAFA.

Namun dengan pertolonganNya, semua itu bisa terlewati dengan mulus, eh ... meski kenyataannya ya setiap hari harus berlomba dengan waktu, --tapi rasanya seperti mengalir saja tau-tau lulus di semester 7.

Semakin terasa keberkahan Al-Quran, mudah dan mengalir begitu saja untuk urusan lain di luar mengajar di Rutaba MQA. Siapa lagi kalau bukan Allah langsung yang menolong? :')

✾ Sampai pada titik ini. Saya harus berpisah raga dari lingkungan Rutaba MQA untuk melanjutkan perjalanan baru, di tempat, dan aktivitas yang baru. Semoga tali silaturahim selalu terjaga dan ikatan keluarga yang sebelumnya dirasakan bisa bersambung untuk waktu-waktu selanjutnya.

Terima kasih sudah menjadi orang tua ideologis bagi saya, Umi Waliko. Terima kasih Umi dan teman2 asatidz sudah menerima, membimbing, dan belajar bareng di Rutaba MQA.

Puji syukur pada Allah Swt. telah diberi kesempatan menjadi keluarga Yayasan MQA.

Sehat selalu dan berlimpah keberkahan bagi asatidz, santriwan/wati, wali santri Yayasan MQA.

Aaamiin Yaa Rabbal 'Aalamiin.

Selasa, 27 Agustus 2024 | Gununglurah, Cilongok

[teamfortresstwo]

https://enchroma.co.uk/pages/colour-blind-test?enchrdrdct=hrd&multisite-redirected=1#multisite-redirected

I CAN TELL ITS “OBJECTIVELY” ORANGE YOU CUNT BUT ITS CLEARLY *INTENDED* TO BE RED .

[industryresearchnew]

PARP Inhibitor Biomarkers: The Future of Precision Oncology

The global PARP (Poly(ADP-Ribose) Polymerase) inhibitor biomarkers market is experiencing notable growth, driven by the increasing prevalence of cancer, advancements in precision medicine, and the rising demand for effective personalized therapies. The market, which focuses on the development and application of PARP inhibitors as a treatment for various types of cancers, is projected to expand significantly over the next several years. In particular, the integration of biomarkers with PARP inhibitor therapies holds immense promise in optimizing treatment outcomes, improving survival rates, and reducing the side effects of cancer treatments.

The Rise of PARP Inhibitors in Cancer Treatment

PARP inhibitors are a class of drugs designed to interfere with the function of the PARP enzyme, which plays a key role in repairing DNA damage in cells. In cancer cells, particularly those with deficiencies in DNA repair mechanisms, PARP inhibitors induce synthetic lethality, effectively triggering cancer cell death. This has made PARP inhibitors particularly effective in treating cancers like breast, ovarian, and prostate cancers, which are often characterized by specific DNA repair defects, such as mutations in the BRCA1 and BRCA2 genes.

The breakthrough role of PARP inhibitors has significantly altered the landscape of cancer therapy, offering new hope to patients who have limited treatment options. However, the optimal use of these therapies relies heavily on the identification of biomarkers, which can predict how well a patient will respond to PARP inhibition.

The Role of Biomarkers in Personalized Cancer Therapy

Biomarkers are crucial in identifying which cancer patients are most likely to benefit from PARP inhibitor treatments. These biological markers, which can be found in blood, tissues, or other bodily fluids, help doctors tailor treatments to individual patients based on the molecular and genetic characteristics of their cancers. Biomarker testing is an integral part of personalized medicine, and it is transforming how oncologists approach cancer treatment.

The biomarkers most commonly associated with PARP inhibitors are those related to the BRCA gene mutations, such as BRCA1 and BRCA2, which are involved in DNA repair. Patients with these mutations are more susceptible to the effects of PARP inhibitors because their tumors already exhibit deficiencies in DNA repair mechanisms. However, ongoing research has uncovered additional biomarkers, including those related to homologous recombination deficiency (HRD), that can expand the pool of patients who may benefit from PARP inhibitors.

For example, the FDA-approved PARP inhibitors like olaparib, rucaparib, and niraparib have demonstrated efficacy in treating cancers that are not limited to BRCA mutations, but instead, those with broader HRD profiles. This opens up the possibility of treating a wider array of patients, further driving the demand for biomarker testing and integration in the treatment decision-making process.

Market Dynamics: Growth Drivers and Challenges

The PARP inhibitor biomarkers market is experiencing robust growth, driven by several key factors:

Increasing Cancer Prevalence: The rising incidence of cancers worldwide, particularly breast, ovarian, and prostate cancers, has contributed to the growing need for effective treatments like PARP inhibitors. According to the World Health Organization (WHO), cancer is the second leading cause of death globally, and the number of cancer cases is expected to increase in the coming years due to factors such as an aging population, lifestyle changes, and environmental factors.

Advancements in Precision Medicine: The shift toward precision medicine is reshaping cancer therapy. By focusing on individual genetic and molecular profiles, treatments can be better targeted to the specific needs of each patient. As more genetic testing and biomarker analysis become routine in clinical practice, the market for PARP inhibitors is set to benefit, with more patients being matched to appropriate therapies based on their biomarker profiles.

Evolving Cancer Treatment Landscape: The availability of PARP inhibitors and their potential applications in various cancer types have expanded significantly in recent years. These drugs are now approved for use in both early and late-stage cancers, and ongoing clinical trials continue to explore their use in other cancer types. As new indications emerge, the market is poised to see continued expansion.

Growing Number of FDA Approvals: The approval of PARP inhibitors by regulatory agencies such as the U.S. Food and Drug Administration (FDA) has been a significant milestone for the market. The success of existing treatments like olaparib (Lynparza) and rucaparib (Rubraca) has paved the way for additional drugs in the pipeline, leading to greater treatment options for patients and contributing to the overall growth of the market.

Despite these positive growth drivers, the market faces certain challenges:

High Treatment Costs: One of the major barriers to the widespread adoption of PARP inhibitors is their high cost. While these therapies offer significant benefits for cancer patients, the high price of treatment can limit access, particularly in low-income regions or for patients without adequate insurance coverage. Lowering the cost of these drugs or increasing insurance reimbursement rates could help mitigate this challenge.

Resistance and Limited Efficacy in Some Patient Populations: Although PARP inhibitors have shown great promise, not all patients respond equally well to these therapies. Resistance to PARP inhibition can develop over time, which limits their long-term effectiveness. Moreover, PARP inhibitors are primarily effective in tumors with specific genetic mutations or defects in DNA repair mechanisms, which means their application is not universal across all cancer patients. Continued research into overcoming resistance and identifying new biomarkers is essential to addressing these limitations.

Regulatory and Market Access Hurdles: Regulatory approval processes for new drugs and therapies can be lengthy and complex. In addition, market access and reimbursement rates vary across regions, affecting the global availability and affordability of PARP inhibitors. Expedited approval processes and improved international collaboration could help address these barriers.

Key Players in the PARP Inhibitor Biomarkers Market

Several key players are shaping the PARP inhibitor biomarkers market, including pharmaceutical companies, biotechnology firms, and diagnostic companies. Some of the most prominent names in the market include:

AstraZeneca: A leader in the PARP inhibitor market, AstraZeneca’s olaparib (Lynparza) has been one of the most successful drugs in the class, receiving multiple approvals for various cancer indications. The company continues to lead in advancing new clinical trials and expanding the use of PARP inhibitors in oncology.

Clovis Oncology: Clovis Oncology is behind rucaparib (Rubraca), another FDA-approved PARP inhibitor. The company is focusing on expanding the indications for rucaparib and exploring its use in combination therapies.

GSK: GlaxoSmithKline (GSK) has developed niraparib (Zejula), a PARP inhibitor that is approved for use in ovarian cancer and other cancers. GSK is also engaged in ongoing research to explore the broader applications of PARP inhibition.

Pfizer: Pfizer is a major player in the oncology market, with a focus on developing targeted therapies and biomarker-driven treatments. The company’s ongoing research in the field of DNA repair mechanisms complements its efforts in the PARP inhibitor space.

Novartis: Novartis is another major pharmaceutical company involved in the development of PARP inhibitors, including efforts to expand their use in various cancer types.

In addition to these pharmaceutical giants, a number of diagnostic companies are developing biomarker tests to complement PARP inhibitor therapies. These tests are essential for identifying patients who are most likely to benefit from PARP inhibitors, thus driving demand for biomarker-based personalized treatments.

Future Outlook and Opportunities

The PARP inhibitor biomarkers market is expected to continue its rapid growth as new research and development efforts lead to the discovery of additional biomarkers, as well as new PARP inhibitor drugs and therapies. The market presents numerous opportunities for stakeholders, including pharmaceutical companies, biotech firms, healthcare providers, and diagnostic companies, to capitalize on the rising demand for personalized cancer therapies.

Additionally, the growing emphasis on precision medicine, along with increasing patient awareness and advocacy, is likely to boost the adoption of PARP inhibitors in the clinical setting. As the understanding of cancer genetics and biomarkers deepens, the potential for even more targeted and effective therapies will continue to evolve.

With ongoing innovations in both PARP inhibitor therapies and biomarker testing, the future of cancer treatment looks promising, offering new hope to patients worldwide and reshaping the oncology landscape for years to come.

[alfahrd]

https://alfahrd.com/service/engineering-recruitment-agency/

Software Engineer Jobs in Dubai |Alfa Hrd Are you Looking for Software Engineer Jobs in Dubai ? We are a trusted job provider agency connecting skilled professionals with leading tech companies. From development to system design and testing, Alfa Hrd offer opportunities across various specializations. Our Alfa Hrd expert team ensures a seamless hiring process, helping candidates secure the right roles and advance their careers in the technology sector.

[purrnaama]

Test DISC Febr 2024

Febr,2024 Nah, ini ada test DISC gua kedua kalinya, di test ini juga sama ini dibacakan oleh HRD gua langsung. most : negotiatorleast : perfectionistchange : establisher type kepribadian D Memiliki rasa ego yang tinggi dan cenderung invidualis dengan standard yang sangat tinggi. Lebih suka menganalisa masalah sendirian daripada bersama orang lain. Rasa egoisnya yang kuat membuatnya tidak…

[sudheervanguri]

Ipca Laboratories, a globally recognized leader in the pharmaceutical industry, is currently seeking experienced professionals to join their Quality Control (QC) Department. Job Details Company: Ipca Laboratories Ltd. Department: Quality Control (QC) – ODS Formulation Unit Location: Gandhi Dham, Gujarat Position: Officer, Sr. Officer, Executive Experience: 4 to 6 years in the QC department of a pharmaceutical company Education: BSc in Chemistry or B Pharmacy Application Deadline: 30 days’ notice period Responsibilities for Quality Control Roles As a Quality Control Officer, Sr. Officer, or Executive at Ipca Laboratories, you will play a key role in maintaining and improving the company’s quality standards. Your responsibilities will include: Sample Analysis: Conducting routine and non-routine testing of raw materials, in-process materials, and finished products to ensure quality standards. Documentation: Maintaining detailed reports of analytical findings and quality checks, ensuring compliance with Good Laboratory Practices (GLP) and regulatory standards. Instrument Handling: Operating and maintaining sophisticated laboratory instruments such as HPLC, GC, FTIR, and UV spectrophotometers. Quality Assurance: Working closely with the production team to ensure that the products meet the desired specifications and regulatory requirements. Compliance: Assuring that all processes adhere to cGMP (Current Good Manufacturing Practices) guidelines and international regulatory standards. Qualifications & Skills To be eligible for the Quality Control roles at Ipca Laboratories, candidates must have the following qualifications and skills: Education: A B.Sc. in Chemistry or Bachelor of Pharmacy (B Pharmacy) from a recognized institution. Experience: A minimum of 4 to 6 years of relevant experience in the Quality Control department of a pharmaceutical company, preferably in an ODS Formulation Unit. Technical Skills: Proficiency in operating laboratory instruments such as HPLC, GC, and UV spectrophotometers. Knowledge of Good Laboratory Practices (GLP) and Current Good Manufacturing Practices (cGMP). How to Apply Avneesh Patel, Sr. Officer - HRD Email: avneesh.patel@ipca.com Shivendra V. Singh Email: shivendrav.singh@ipca.com When applying, please include the following details: Current CTC (Cost to Company) Expected CTC Notice Period Preferred time for telephonic discussion [caption id="attachment_56648" align="aligncenter" width="930"] Ipca Laboratories Hiring for Quality Control - Officer, Sr. Officer, Executive[/caption]

[fresherjobwala]

DRDO ITR Apprentice Recruitment 2024 – 54 Vacancies

DepartmentDefence Research & Development Organization (DRDO), Ministry of Defence, Integrated Test Range ChandipurTotal Vacancies54Notification No.ITR/HRD/AT/09/2024Application Deadline07-10-2024 Basic Information PositionsGraduate Apprentice, Technician ApprenticeLocationOrissaQualificationDiploma/DegreeApplication ProcedureOffline DRDO-ITR has released a recruitment notification…

[cattutorialsblogs]

Information bout The Common Admission Test

The Common Admission Test (CAT) is a PC based test held in India. The check ratings a competitor on the bases of Quantitative Ability (QA), Verbal Ability (VA) and Reading Comprehension (RC), Data Interpretation (DI) and Logical Reasoning (LR). The Indian Institutes of Management (IIMs) started this exam and utilize the take a look at for deciding on understudies for his or her commercial enterprise corporation packages. Let’s start your CAT Exam preparation with theBest CAT Online Coaching.  The take a look at is led every year with the aid of one of the IIMs in light of a strategy of revolution.

In August 2011, it turned into declared that Indian Institutes of Technology (IITs) and Indian Institute of Science (IISc) would likewise utilize the CAT rankings, instead of the Joint Management Entrance Test (JMET), to choose understudies for their administration applications starting with the 2012–14 batch. Cat examination

2015 become led by way of the Indian Institute of Management Ahmedabad (IIM Ahmedabad) on November 29, 2015. IIM Indore held Common Admission Test for the two successive years 2013 and 2014.

Qualification for CAT

The competitor must satisfy the beneath indicated criteria’s:

1. Hold a Bachelor’s Degree, with out a below half of or equal CGPA (forty five% if there ought to emerge an occasion of the hopefuls having an area with Scheduled Caste (SC), Scheduled Tribe (ST) and Persons with Disability (PWD)/Differently Able (DA) characterization)

2. The degree ought to be conceded by means of any of the Universities united by using an indication of the focal or kingdom statutory body in India or different educational associations evolved by using a demonstration of Parliament or articulated to be considered as a University below Section 3 of the UGC Act, 1956, or have a proportional functionality perceived by means of the Ministry of HRD, Government of India.

3. Contenders showing up for the ultimate yr of four 12 months university schooling/same capability examination and the human beings who have completed degree necessities and are suspecting outcomes can similarly follow. In the occasion that chose, such candidates might be allowed to join the program incidentally, just within the event that she/he indicates a announcement cutting-edge by using June 30, 2018 from the Principal/Registrar of her/his College/Institute (issued on the most current June 30, 2018) speaking that the contender has completed every one of the necessities for shopping the 4 year faculty training/indistinguishable potential at the date of the difficulty of the test omony.

Confuse about How to start CAT preparation, join the CAT Online Coaching Classes.

Test layout and length

Feline Exam Pattern is uncommon and it modifications each year. Since most current two years, the shape of the test has skilled more than one adjustments. According to the awareness discharged via IIM Lucknow, there is no such trade offered in cat examination pattern 2017. Feline is a PC primarily based take a look at which accommodates of a hundred targets write questions. There are three segments in the take a look at:

•Verbal and Reading Comprehension (VARC)

•Data Interpretation and Logical Reasoning (DI and LR)

•Quantitative Ability (QA)

The Quantitative Ability and Verbal and Reading Comprehension areas comprised 34 addresses each, whilst the Data Interpretation and Logical Reasoning section had 32 questions. This move of inquiries became same for CAT 2015 and CAT 2016. Before this, the dissemination of inquiries turned into unique. In CAT 2017, it’s miles everyday that diverse inquiries in every segment might also differ when contrasted with the earlier year.

For CAT 2017, IIM Lucknow has discharged a few focuses diagnosed with CAT Exam Pattern, for example,

•A few inquiries in every region of CAT is probably of non-MCQs write questions (TITA-Type In The Answer).

•Exactly an hour will be apportioned for noting every region.

•Each query conveys three marks and there’s poor stamping of 1 test for each wrong answer.

•No terrible checking for non-MCQ writes questions.

•A virtual including device (on-display screen including system) might be handy all through with the stop intention of the count.

The take a look at takers can’t transfer among the segments and want to visit the take a look at in a particular request. The request of the segments is identical for each one of the applicants

•VARC

•DI and LR, and

•QA

Four scaled ratings may be exhibited for every applicant: a popular scaled score and three separate scaled scores for each phase. As the three regions check unmistakable preparations of mastering and skills, scores don’t connect crosswise over segments. A excessive rating in one segment does now not make certain a high rating in any other area. Percentile ratings are accommodated each man or woman region and additionally for the general exam rating.

[industryhub]

Exciting Placement Activities at Dr. D. Y. Patil Educational Complex, Akurdi

Welcome to the hub of opportunities and learning—Dr. D. Y. Patil Educational Complex, Akurdi. Here, we believe in equipping our students with the skills and knowledge required to excel in their careers. Our robust placement activities are a testament to our commitment to student success. Let’s take a closer look at the vibrant events and initiatives that have recently taken place on our campus.

Bitwise Career Counseling Session

In July 2019, we kicked off our placement activities with a career counseling session organized by Bitwise. This session was designed to provide students with valuable insights into career planning and the various paths they can pursue post-graduation.

HR Meet on 10th August 2019

On August 10th, 2019, we hosted an HR Meet, which brought together industry leaders and our students. This event provided an excellent platform for students to interact with HR professionals, understand industry expectations, and learn about the latest trends in human resource management.

Leadership Talk Series by HRD Minister Dr. Ramesh Pokhriyal

Innovation is the key to a resurgent India. On August 22nd, 2019, our students had the privilege to attend a webinar on this very topic, conducted by HRD Minister Dr. Ramesh Pokhriyal. The session was enlightening and inspired our students to think creatively and innovatively.

National Business Quiz Participation

On August 27th, 2019, our students participated in the National Business Quiz organized by the NIPM Pune chapter. This was a fantastic opportunity for our students to test their business acumen and compete with peers from across the country.

Effective Interview Skills Session

Interview skills are crucial for any job seeker. On September 3rd, 2019, students from our MBA department attended a session on effective interview skills, organized by the HPCL training center. The session was conducted by Dr. Robert Emmerling, an international expert from Spain, who provided valuable tips and techniques to ace interviews.

Resume Writing Workshop

A well-crafted resume is the first step towards securing a job. On September 28th, 2019, Prof. Shivam Nirmale from our English Language Lab conducted a resume writing workshop for MBA 1st-year students. The workshop was highly interactive and provided students with practical insights into creating impactful resumes.

Seminar on Skill Requirements for Industry 4.0

The future is here, and it is called Industry 4.0. To prepare our students for this future, we organized a seminar by Rohit Ghosh on the skills required for Industry 4.0. The seminar highlighted the importance of digital skills, automation, and data analytics in the modern industry landscape.

Expert Sessions on AWS Cloud

Cloud computing is a game-changer in today's IT industry. We were honored to have Nirao Sanghvi conduct an expert session on AWS Cloud for our students. The session provided deep insights into cloud technologies and their applications in various industries.

NEURON 2019: DYP Hackathon

Innovation was at its peak during NEURON 2019, the DYP Hackathon organized on February 22nd, 2019, in collaboration with technology partners Xoriant Solutions and ESDS. This event saw enthusiastic participation from students who showcased their problem-solving skills and technical expertise.

Industrial Visit to Persistent Systems, Hinjewadi

Understanding the workings of the industry is crucial for students. Our students had an enlightening industrial visit to Persistent Systems in Hinjewadi. This visit provided them with a glimpse into the corporate world and the operations of a leading IT company.

Expert Talk by Mr. Rohit Singla

We were privileged to host Mr. Rohit Singla, Chief Transformation Officer at BMC Software, for an expert talk. His session was highly motivating and provided students with insights into the digital transformation journey of leading organizations.

Congratulations to Japanese Language Certification Achievers

We extend our hearty congratulations to Mr. Rajdeep Malakar from TE E&TC and Ms. Rutuja Kalbhor from SE Computer for clearing the N5 level of the Japanese Language Certification. This achievement is a testament to their hard work and dedication.

TCS Hikari Programme Inauguration

One of the highlights of our placement activities is the TCS Hikari Programme. We are proud to have TCS assist our colleges in training students for the Japanese Language. The inauguration of this program took place on January 19th, 2016, at the Shantai Auditorium. The event was graced by distinguished guests including Mr. Toshimitsu Urabe, Executive Vice President and Group CEO of the Business Service Group at Mitsubishi Corporation, Mr. K Ganesan, Vice President, Human Resources, TCS, and Mr. TV Kamalakkannan, Chief Delivery Officer and a Member of the Board of Nihon TCS Japan. The presence of Col. S. K. Joshi, Campus Director, along with Principals, HODs, and students, made the event truly memorable.

Conclusion

At Dr. D. Y. Patil Educational Complex, Akurdi, we are committed to providing our students with the best opportunities for learning and growth. Our placement activities are designed to prepare students for the challenges of the professional world and help them achieve their career goals. Stay tuned for more updates on our exciting events and initiatives!

[businessinsiderofpakistan]

Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries

http://dlvr.it/T87R3W

[upstartly]

Jst tstng t s hw sy t s t rd smthng wth n vwls n t n nglsh

Bvsly th lngr wrds r sr bcs thrs lss weds t cld b bt lk my gd ts knd hrd lk lk t sr nd lk nd lk tgthr

-------

Just testing to see how easy it is to read something with no vowels in it in english

Obviously the longer words are easier because there's less words it could be but like my god its kinda hard like look at easier and like and look together

[neerajsharmadell]

Neeraj Sharma: Pioneering Customer Satisfaction at Dell and Lenovo

Nee­raj Sharma, a seasoned professional in the tech industry, made­ a difference in custome­r satisfaction at both Lenovo and Dell. His strategic plans and de­dication towards improving customer experie­nces have create­d high standards in the field. This marks him as a paragon of customer centricity.

Lenovo: Redefining Customer Relations

During his time at Lenovo, Neeraj Sharma le­d changes that totally transformed the company’s approach towards customer satisfaction. He knew how important it was to have­ good relationships with customers in the supe­r tough tech world. So, he started programs that focuse­d on proactive engagement.

Sharma's standout initiative was creating an exclusive syste­m for customer feedback. This was not just about gathering vie­ws but promoting engagement and action. Custome­r responses turned into a guide­ for improving products and services, guiding Lenovo to focus more­ on the customer.

Neeraj Sharma served on the Internal Board for Lenovo India while managing the entire P&L, talent management, customer & employee satisfaction, and plant infrastructure. He was awarded as one of the CEOs with HR Orientation in the Asia Pacific HRM Congress, 2007, and as one of the Top 20 CEOs in India with people touch by the India HRD Congress for his exceptional performance. During his time, Lenovo achieved market leadership and became the #1 customer satisfaction company in first year, as per DQ CIO’s survey.

In a market full of options, Sharma kne­w everyone ne­eded individualized atte­ntion. He strongly supported using custom-fit strategie­s, realizing each case is unique­. By giving targeted help and solving proble­ms uniquely, Lenovo stood out under Sharma's guidance­. This made customers fee­l special and strengthene­d their commitment to the brand.

Dell: Striving for Excellence

When Ne­eraj Sharma moved to Dell, his tire­less chase for customer happine­ss didn't end. He knew the­ importance of support after buying, so he se­t up a strong network to help customers post-purchase­. Neeraj Sharma believed that even though the initial sale was crucial, but the real test of a company’s commitment towards their customers lies in the support provided after the sale. Thus, the goal now was not just about selling products. It was about making customers fe­el cared for and valued during the­ir product's lifespan.

Neeraj Sharma designed a game-changer account management strategy in Dell for 20+ customers, initiating it with a focused conversation with the CIO/CXOs but seamlessly implemented by 60-member team with diverse skill sets. He catered to the diverse needs of clients from the entire portfolio of Dell, including PC products, storage solutions to specific products.

Under Neeraj Sharma, Dell made custome­r focus a core part of the business. They pushed teamwork across departme­nts, getting rid of division walls and encouraged cross functional collaboration. This resulted in a full-scale­ method to fix issues, leading to faste­r solutions and happier customers.

Key takeaway’s from Neeraj Sharma’s approach

1) Active listening and responsiveness

Neeraj Sharma highlights the importance of active listening. Active listening is not just about collecting the customers' opinions but also responding proactively to those opinions. They must use these opinions as a catalyst for change.

2) Customization and Tailored solutions

Neeraj Sharma understood the diversity among the customers and treated each customer as a unique individual. Thus he necessitated personalized solutions for different customers that fit their needs.

3) Empowerment and Collaboration

Sharma's approach centers on empowe­ring those on the frontlines and collaborating among departments. It's about bringing te­ams together to solve proble­ms. This synergy ensures a more holistic approach to problem-solving, resulting in enhanced customer satisfaction.

The legacy of Neeraj Sharma

Nee­raj Sharma's legacy of customer satisfaction at Lenovo and Dell shows his forward-thinking leade­rship and solid dedication. His plans and focus on the­ customer satisfaction offer guideline­s for their sector. They highlight how crucial happy custome­rs are for long-term business succe­ss.

As other companies try to emulate his efforts, Neeraj Sharma's record shine­s bright, lighting the path towards better custome­r service and building enduring partne­rships in the tech sector.